Operationalizing Treatment with Bispecifics for Multiple Myeloma : Episode 10

Opinion

Video

March 11, 2024

Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM

Carol Ann Huff, MD, describes her institution's multidisciplinary approach to monitoring for adverse events when administering bispecific antibodies, including the roles of nurses, pharmacists, and attending physicians.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Impact of Bispecific Antibodies on Multiple Myeloma Treatment

EP: 2.Key Considerations in Treatment Selection for Patients With Multiple Myeloma

EP: 3.Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody

EP: 4.Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies

EP: 5.The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies

EP: 6.Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma

EP: 7.Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma

EP: 8.Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma

EP: 9.Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma

Now Viewing

EP: 10.Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM

EP: 11.Complying with REMS Training and Documentation Requirements

EP: 12.Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM

EP: 13.Unmet Needs in Multiple Myeloma Care

EP: 14.Treatment Sequencing and Combination Therapies for MM

EP: 15.Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM

EP: 16.Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma

EP: 17.Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials

EP: 18.Identifying Patients Who Are Candidates for Bispecifics and Referring Patients for Care

EP: 19.Collaborating with Other Care Providers to Optimize Outcomes for Patients Receiving Bispecifics

EP: 20.Considerations for Maintenance Therapy in the Community Oncology Setting

EP: 21.Team Approach to Meeting REMS Program Requirements

EP: 22.Role of Pharmacists in Operationalizing Bispecific Antibodies

EP: 23.Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting

EP: 24.Unmet Needs in Relapsed or Refractory Multiple Myeloma

Related Videos

Interdisciplinary Approaches to Breast Cancer Care and ADC Treatment Barriers Due to Social Determinants of Health

Discussing ADC Risks, Benefits, and Regimens With Patients

Leveraging Technology to Enhance Women’s Health and Access to Care

Staying Current Regarding Available Therapeutic Options and Updates to Treatment Guidelines

Optimizing ADC Supportive Care Prescribing and AE Management With Institutional Workflows

Monitoring Strategies for Managing ADC Toxicities in mBC

Examining the 505(b)(2) Pathway and Implementation into EHR

Managing ADC Toxicities and Infusion Reactions With Supportive Care Strategies

Strategies for Supporting Adherence to Treatment and Evaluating Efficacy

Patient Education When Initiating Treatment for Menopausal Symptoms